(MENAFN- GetNews)
"Alpha 1 Antitrypsin Deficiency Pipeline Insight"As per DelveInsight's assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Alpha-1 Antitrypsin Deficiency (AATD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
“ Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Insight, 2024 ” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the
treatment of Alpha-1 Antitrypsin Deficiency
and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the
Alpha-1 Antitrypsin Deficiency market .
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Types
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
Immunomodulators; Serine endopeptidase inhibitors
Alpha 1 antitrypsin modulators
Alpha 1 antitrypsin inhibitors; RNA interference
Leucocyte elastase inhibitors
Alpha 1 antitrypsin modulators; RNA interference
Learn How the Ongoing Clinical & Commercial Activities will Affect the Alpha-1 Antitrypsin Deficiency Therapeutic Segment @
Alpha-1 Antitrypsin Deficiency Therapeutics Landscape
There are approx.
12+ key companies
developing therapies for Alpha1-Antitrypsin Deficiency (AATD). Currently,
Arrowhead Pharmaceuticals
is leading the therapeutics market with its Alpha1-Antitrypsin Deficiency (AATD) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Alpha-1 Antitrypsin Deficiency Therapeutics Market Include:
And Many Others
Alpha1-Antitrypsin Deficiency (AATD) Drugs Covered in the Report Include
ALN-AAT02: Alnylam Pharmaceuticals
Alvelestat: Mereo Biopharma)
ARO AAT: Arrowhead Pharmaceuticals
DCR-A1AT: Dicerna Pharmaceuticals, Inc.
INBRX-101: Inhibrx, Inc.
Kamada-AAT for Inhalation: Kamada, Ltd.
VX-864: Vertex Pharmaceuticals Incorporated
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Contents
1. Report Introduction
2. Executive Summary
3. Alpha-1 Antitrypsin Deficiency Current Treatment Patterns
4. Alpha-1 Antitrypsin Deficiency – DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase-III)
7. Alpha-1 Antitrypsin Deficiency Mid-Stage Products (Phase-II)
8. Alpha-1 Antitrypsin Deficiency Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alpha-1 Antitrypsin Deficiency Discontinued Products
13. Alpha-1 Antitrypsin Deficiency Product Profiles
14. Key Companies in the Alpha-1 Antitrypsin Deficiency Market
15. Key Products in the Alpha-1 Antitrypsin Deficiency Therapeutics Segment
16. Dormant and Discontinued Products
17. Alpha-1 Antitrypsin Deficiency Unmet Needs
18. Alpha-1 Antitrypsin Deficiency Future Perspectives
19. Alpha-1 Antitrypsin Deficiency Analyst Review
20. Appendix
21. Report Methodology
Download Sample PDF to
Explore
the Key Offerings of the Report @
MENAFN22052024003238003268ID1108247248
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.